Skip to content
DataLookout
Menu

NCT06791525

Tirbanibulin for Pediatric Warts

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words Show 4 more changesShow less
    • Trial completed
    • Final enrollment: 7 participants (planned 10)
    • Study completion date changed from estimate of Dec 30, 2026 to Nov 5, 2026
    • Site details revised
  2. Notable Primary completion date: Nov 1, 2025 to Nov 1, 2026
    • Study completion date: Dec 30, 2025 to Dec 30, 2026
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2025 to May 1, 2025
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Resolution
Timeframe: 2 months aftre completion of 4 or less treatment cycles

Arms and interventions

Topical treatment armExperimental

Topical medication self-applied

Drugs: Tirbanibulin ointment 1%

Sites

1 site in 1 country

  • The Skin Center Dermatology GroupNew City, New York, United States